Sequential therapy in stage IV melanoma – real-world SECOMBIT Teresa Amaral*1,2, Olivia Seber1, Stephanie Sanchez1, Ulrike Keim1, Ioannis Thomas1, Andreas Meiwes1, Andrea Forschner1, Thomas Eigentler1, Claus Garbe1 1 Centre for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany 2 Portuguese Air Force Health Care Direction, Lisbon, Portugal   Corresponding Author: Teresa Amaral Email: Teresa.Amaral@med.uni-tuebingen.de […]

Reverse transcriptase inhibition potentiates target therapy in BRAF-mutant melanomas: an in vitro study Luigi Fattore*1,2, Gianluca Sbardella3, Gerardo Botti2, Rita Mancini4, Paolo A. Ascierto2 and Gennaro Ciliberto5 1 SAFU Laboratory, Department of Research, Advanced Diagnostics and Technological Innovation, Translational Research Area, IRCCS Regina Elena National Cancer Institute, Rome, Italy 2 Istituto Nazionale Tumori IRCCS, “Fondazione […]

The impact of brain involvement in metastatic melanoma patients treated with pembrolizumab Michael Weichenthal1,2*, Scherrer Emilie3, Sheenu Chandwani3, Peter Mohr 4,5 Ulrike Leiter6, Selma Ugurel7, Katharina C. Kähler1,8, Ralf Gutzmer9, Claudia Pföhler10, Jessica Hassel11, Patrick Terheyden12, Beatrice Schell13, Jochen Utikal14: Alexander Kreuter15, Sebastian Haferkamp16, Anca Sindrilaru17, Jessica Hassel18, Dorothee Nashan19, Kjell M. Kaune20, Carola Berking21, […]

Background: Guidelines for follow-up of patients with melanoma are based on limited evidence. Objectives: To guide skin surveillance, we developed a risk prediction model for subsequent primary melanomas, using demographic, phenotypical, histopathological, sun exposure and genomic risk factors. Methods: Using Cox regression frailty models, we analysed data for 2613 primary melanomas from 1266 patients recruited […]

Importance  In recent years, the management of metastatic melanoma has been transformed by the emergence of immune checkpoint inhibitors and targeted therapies that significantly improve patient survival. The complementary response kinetics of these treatment approaches, supported by mechanistic evidence that targeted therapy affects immune aspects of the tumor microenvironment, suggest that the optimal combination or […]

Importance  To date, the risk of developing second primary cancers (SPCs) after the first primary melanoma has not been studied in the era of immune checkpoint inhibitors (ICIs). Objective  To assess differences in the risk of SPCs in patients with primary melanoma before (2005-2010) and after (2011-2016) the introduction and approval of ICIs. Design, Setting, […]

Background Adjuvant targeted therapy (TT) improves relapse free survival in patients with resected BRAF mutant stage III melanoma. The outcomes and optimal management of patients who relapse after adjuvant TT is unknown. Methods Patients from twenty-one centres with recurrent melanoma after adjuvant TT were included. Disease characteristics, adjuvant therapy, recurrence, treatment at relapse and outcomes […]

The melanoma field has seen an unprecedented set of clinical advances over the past decade. Therapeutic efficacy for advanced or metastatic melanoma went from being one of the most poorly responsive to one of the more responsive. Perhaps most strikingly, the advances that transformed management of the disease are based upon modern mechanism-based therapeutic strategies. […]

Background: Neo-adjuvant approaches in locally advanced melanoma have been shown to improve outcomes and facilitate translational research in order to identify biomarkers of response and resistance. In particular, pathological responses at surgery seem to work as a surrogate of survival. We investigated the efficacy and safety of Ipilimumab/Nivolumab combination as primary treatment of locally advanced […]